[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345546-105":59,"doc-detail-345546-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-prevalence-among-large-cohort-of-individuals-with-down-syndrome-implications-for-screening-guidelines","Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome - Implications for Screening Guidelines","","This retrospective cohort study evaluates cancer prevalence patterns in a large U.S. Down syndrome (DS) population using 24 years of EHR data from 5,895 individuals. Point prevalence for each cancer type was derived from ICD-10 coding, assessed for co-occurrence, and compared with U.S. general-population rates using SEER data (2022). Results show DS individuals have lower overall cancer odds (OR 0.88) with markedly reduced solid tumor prevalence, contrasted by higher leukemia and testicular cancer prevalence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-prevalence-among-large-cohort-of-individuals-with-down-syndrome-implications-for-screening-guidelines/345546/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-prevalence-among-large-cohort-of-individuals-with-down-syndrome-implications-for-screening-guidelines/345546.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s data source and design?","Question",{"text":112,"@type":113},"The study used a retrospective cohort design based on 24 years of EHR data from 5,895 unique individuals with Down syndrome in a Midwestern U.S. health system.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did cancer odds in the Down syndrome cohort compare with the general population?",{"text":117,"@type":113},"Individuals with Down syndrome had significantly lower overall odds of cancer versus the general population (OR = 0.88, 0.77–0.99).",{"name":119,"@type":110,"acceptedAnswer":120},"What screening-related implication did the study draw from prevalence differences?",{"text":121,"@type":113},"The study concluded that cancer screening recommendations should be modified for people with Down syndrome and incorporated into shared decision-making with patients and their families.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345546,1790126177,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nCancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines  \nVeronica Fitzpatrick1,2  | Akaninyene Noah1,2  | Anne Rivelli1,2 | Rachel Johnson3 | Melissa Zak3 | Joaquin Espinosa4 | Brian Chicoine2,5   \n1Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA | 2Advocate Health Oak Brook Support Center, Oak Brook, Illinois, USA | 3Aurora Medical Group, Milwaukee, Wisconsin, USA | 4Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA | 5Advocate Medical Group Adult Down Syndrome Center, Park Ridge, Illinois, USA  \nCorrespondence: Veronica Fitzpatrick ([veronica.fitzpatrick@aah.org](veronica.fitzpatrick@aah.org))  \nReceived: 8 May 2025 | Revised: 7 May 2026 | Accepted: 24 May 2026  \nKeywords: cancer | down syndrome | healthcare guidelines | prevalence | trisomy 21  \nABSTRACT  \nIntroduction: It is known that individuals with Down syndrome (DS) have a significantly different spectrum of malignancies and neoplasms. Research shows that most solid tumors are less common among individuals with DS compared to the general population, even when adjusted for age. Conversely, individuals with DS are more likely to develop leukemia and testicular cancer. However, very little of this research has been conducted with a US-based population or on large sample sizes.  \nMethods: This retrospective cohort study analyzed 24 years of EHR data from 5895 unique individuals with DS seen in a Midwestern US health system, with the largest designated DS clinic in the US. We calculated the point prevalence of each cancer type, based on ICD-10 coding, in our DS cohort, examined co-occurrence patterns, and compared prevalence within our sample to the US general population using SEER data from 2022.  \nResults: Individuals with DS have significantly lower odds of cancer than the general population (OR = 0.88 (0.77–0.99)) . Our cohort was 50.2% less likely to have skin cancer, 80.1% less likely to have cervical cancer, 91% less likely to have prostate cancer, and 90% less likely to have breast cancer. Zero people in our DS cohort had lung cancer. Conversely, our cohort was more likely to have leukemia and testicular cancer.  \nConclusion: The differences in prevalences indicate a need to consider modification of the cancer screening recommendations for people with DS and inclusion of the information in shared-decision making conversations with the patient and their family.  \n1 | Introduction  \nDown syndrome (DS) is the most common chromosomal condition in the world [1, 2] . In the United States (US) specifically, DS occurs in 1 of every 700 live births in the US [3], accounting for approximately 206,000 people living with DS [4], thoughthe exact and current prevalence is unknown because of lack of data and changing survival rates across decades. Average life expectancy for people with DS has substantially increased over the past few decades, from 25 years in 1983 to nearly 60 years in 2020 [5] . The population of people with DS increased more  \nthan four-fold in the US from 1950 to 2010 (49,923 to 206,366) with the number of adults (age 20 and above) with DS increasing seven times during that same period (13,368 to 117,763) [6] .  \nCancer is the second leading cause of death in the US and globally, and it puts an immense physical, emotional and financial strain on individuals, families, communities and health systems [7, 8]. National health screening and treatment guidelines reflect the prevalence of cancer [9]; however, it is becoming evident that individuals with DS have significantly different odds of certain cancers compared to those without DS, indicating current  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commerci","cbCaidFUklh9cnBp","https://ap.wps.com/l/cbCaidFUklh9cnBp","pdf",850683,12,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Down syndrome epidemiology\n## Cancer burden and guideline relevance\n# Cancer prevalence in DS compared with general populations\n## Meta-analysis and international cohort findings\n# Solid Tumors\n## Overall risk and key exceptions","[{\"question\":\"What was the study’s data source and design?\",\"answer\":\"The study used a retrospective cohort design based on 24 years of EHR data from 5,895 unique individuals with Down syndrome in a Midwestern U.S. health system.\"},{\"question\":\"How did cancer odds in the Down syndrome cohort compare with the general population?\",\"answer\":\"Individuals with Down syndrome had significantly lower overall odds of cancer versus the general population (OR = 0.88, 0.77–0.99).\"},{\"question\":\"What screening-related implication did the study draw from prevalence differences?\",\"answer\":\"The study concluded that cancer screening recommendations should be modified for people with Down syndrome and incorporated into shared decision-making with patients and their families.\"}]","Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome - Implications for Screening Guidelines | PDF",1790058053]